Because platelet counts and hPF4 content per platelet vary in the general population (109, 110) and critically ill individuals often develop thrombocytopenia (111, 112), we propose that septic patients may benefit from either hPF4 and/or Fc-modified KKO infusion to optimize NET stabilization. This evidence concerns the gene ZNF85 and Thrombocytopenia.